购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空

PCSK9 Protein, Cynomolgus, Recombinant (His)

产品编号 TMPK-00483

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene in humans on chromosome 1.The first two PCSK9 inhibitors, alirocumab and evolocumab, were approved as once every two week injections, by the U.S. Food and Drug Administration in 2015 for lowering LDL-particle concentrations when statins and other drugs were not sufficiently effective or poorly tolerated.

PCSK9 Protein, Cynomolgus, Recombinant (His)

PCSK9 Protein, Cynomolgus, Recombinant (His)

产品编号 TMPK-00483
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene in humans on chromosome 1.The first two PCSK9 inhibitors, alirocumab and evolocumab, were approved as once every two week injections, by the U.S. Food and Drug Administration in 2015 for lowering LDL-particle concentrations when statins and other drugs were not sufficiently effective or poorly tolerated.
规格价格库存数量
100 μg¥ 2,6605日内发货
500 μg¥ 10,6005日内发货
1 mg¥ 17,8005日内发货
大包装 & 定制
加入购物车
实验操作小课堂
查看更多
TargetMol 的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。

生物活性

生物活性
1. Immobilized Cynomolgus PCSK9, His Tag at 5μg/ml (100μl/Well) on the plate. Dose response curve Anti-PCSK9 Antibody, hFc Tag with the EC50 of 81.5ng/ml determined by ELISA (QC Test). 2. Cynomolgus LDLR, His Tag immobilized on CM5 Chip can bind Cynomolgus PCSK9, His Tag with an affinity constant of 0.27 nM as determined in SPR assay.
产品描述
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene in humans on chromosome 1.The first two PCSK9 inhibitors, alirocumab and evolocumab, were approved as once every two week injections, by the U.S. Food and Drug Administration in 2015 for lowering LDL-particle concentrations when statins and other drugs were not sufficiently effective or poorly tolerated.
种属
Cynomolgus
表达系统
HEK293 Cells
标签C-His
蛋白编号A0A2K5TZC4
别名
PCSK9
蛋白构建
Glu151-Gln811
蛋白纯度
> 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC
分子量Due to autocatalytic cleavage, the protein release the pro-form (59 kDa) and mature form (14 kDa). Due to glycosylation, the protein migrates to 65-70 kDa (pro-form) and 15-20 kDa (mature form) based on Tris-Bis PAGE result.
内毒素< 1 EU/μg by the LAL method.
缓冲液Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS (pH 7.4). Typically, 8% trehalose is incorporated as a protective agent before lyophilization.
复溶方法
Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.
存储
It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
运输方式In general, Lyophilized powders are shipping with blue ice.
研究背景
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene in humans on chromosome 1.The first two PCSK9 inhibitors, alirocumab and evolocumab, were approved as once every two week injections, by the U.S. Food and Drug Administration in 2015 for lowering LDL-particle concentrations when statins and other drugs were not sufficiently effective or poorly tolerated.

计算器

  • 复溶 计算器
  • 重组蛋白稀释 计算器
  • 比活力 计算器

技术支持

请阅读 重组蛋白用户指南 了解更多具体信息.

关键词